Infinity Pharmaceuticals (INFI) Posts Wide Q4 Miss
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Join SI Premium – FREE
Infinity Pharmaceuticals (NASDAQ: INFI) reported Q4 EPS of ($0.53), $0.14 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $16.96 million.
Sees FY11 net cash burn of $30-$40M, net cash balance at end of year of $60-$70M.
Sees FY11 net cash burn of $30-$40M, net cash balance at end of year of $60-$70M.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
- Bit Digital (BTBT) Misses Q2 EPS by 27c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
